These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27696263)

  • 21. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
    Le Ray E; Jagannath S; Palumbo A
    Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A practical approach to relapsed multiple myeloma.
    Mikhael JR
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):262-7. PubMed ID: 25696865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
    Afifi S; Michael A; Azimi M; Rodriguez M; Lendvai N; Landgren O
    Pharmacotherapy; 2015 Dec; 35(12):1173-88. PubMed ID: 26684557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pomalidomide for multiple myeloma].
    Fouquet G; Macro M; Decaux O; Fohrer C; Guidez S; Demarquette H; Le Grand C; Prodhomme C; Renaud L; Bories C; Herbaux C; Karlin L; Roussel M; Benboubker L; Hulin C; Arnulf B; Leleu X
    Rev Med Interne; 2015 Sep; 36(9):613-8. PubMed ID: 26257103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
    Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
    Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [State of the art treatment of progressive or refractory multiple myeloma].
    Schmidt-Wolf IG; Straka C; Scheid C; Einsele H; Goldschmidt H; Engelhardt M
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2091-5. PubMed ID: 25268212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pomalidomide in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2016 Sep; 12(17):1975-83. PubMed ID: 27283457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
    Jakubowiak A
    Semin Hematol; 2012 Jul; 49 Suppl 1():S16-32. PubMed ID: 22727389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options.
    Ramasamy K; Gay F; Weisel K; Zweegman S; Mateos MV; Richardson P
    Blood Rev; 2021 Sep; 49():100808. PubMed ID: 33863601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
    Jagannath S; Dimopoulos MA; Lonial S
    Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel drug combinations for the management of relapsed/refractory multiple myeloma.
    Usmani SZ; Lonial S
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
    Richardson PG; Laubach J; Mitsiades C; Schlossman RL; Doss D; Colson K; McKenney ML; Noonan K; Warren DL; Ghobrial IM; Munshi NC; Anderson K
    Oncology (Williston Park); 2010 Mar; 24(3 Suppl 2):22-9. PubMed ID: 20518367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of relapsed and relapsed/refractory multiple myeloma.
    Laubach JP; Mitsiades CS; Mahindra A; Luskin MR; Rosenblatt J; Ghobrial IM; Schlossman RL; Avigan D; Raje N; Munshi NC; Anderson KC; Richardson PG
    J Natl Compr Canc Netw; 2011 Oct; 9(10):1209-16. PubMed ID: 21975917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
    van de Donk NW; Lokhorst HM; Dimopoulos M; Cavo M; Morgan G; Einsele H; Kropff M; Schey S; Avet-Loiseau H; Ludwig H; Goldschmidt H; Sonneveld P; Johnsen HE; Bladé J; San-Miguel JF; Palumbo A
    Cancer Treat Rev; 2011 Jun; 37(4):266-83. PubMed ID: 20863623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Choosing treatment options for patients with relapsed/refractory multiple myeloma.
    Castelli R; Orofino N; Losurdo A; Gualtierotti R; Cugno M
    Expert Rev Anticancer Ther; 2014 Feb; 14(2):199-215. PubMed ID: 24329153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic strategies for the treatment of multiple myeloma.
    Saini N; Mahindra A
    Discov Med; 2013 Apr; 15(83):251-8. PubMed ID: 23636142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current therapeutic strategies for multiple myeloma.
    Torimoto Y; Shindo M; Ikuta K; Kohgo Y
    Int J Clin Oncol; 2015 Jun; 20(3):423-30. PubMed ID: 25855312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage therapy of multiple myeloma: the new generation drugs.
    Romano A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Di Martina V; Schinocca E; La Fauci A; Parrinello NL; Chiarenza A; Di Raimondo F
    Biomed Res Int; 2014; 2014():456037. PubMed ID: 24967371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.